PRESS RELEASE

Imaxio and VitamFero launch R&D partnership

Evry (Essonne), 4th of October, 2013

Imaxio and VitamFero announce the conclusion of an R&D partnership agreement. According to the terms of the agreement, the two firms will evaluate the combination of IMX313, Imaxio's pro-immunogenic technology, and VitamFero's live attenuated parasites, for vaccines development.

Imaxio, a biopharmaceutical company based in Lyons, develops a pipeline of vaccines based on its proprietary antigen re-engineering technology, IMX313, that enables significant increase of immunogenicity and efficacy of vaccines with which it is used.

VitamFero, a biotech firm of the Genopole cluster, develops veterinary vaccines against several infectious diseases, essentially parasitic, for which there is a big unmet prophylactic need. To that end, VitamFero uses live attenuated parasitic strains, of which it holds the rights.

Within the framework of this collaboration, Imaxio's IMX313 technology will be combined with VitamFero's live attenuated strains in order to identify immunogenic synergies between the two vaccine approaches, and thus to potentiate the efficacy of future vaccine candidates.

"We welcome the start of this research program in collaboration with Imaxio", enthuses Dr. Edouard SECHE, Scientific Director of VitamFero. "Our goal is to provide responses and perspectives to prevent major parasitic diseases against which we are still largely empty-handed."

"Identifying new synergies between vaccine technologies is a major opportunity to respond to the lack of efficacy of certain products in development," adds Mr. Alexandre LE VERT, Chief Executive Officer of Imaxio. "We are pleased to perform such research with VitamFero and hope that it will subsequently lead to the development of a vaccine candidate."

Contact presse : Véronique Le Boulc'h – veronique.leboulch@genopole.fr - 01 60 87 44 98

About VitamFero. Created in 2005, the firm **VitamFero** exploits major conjoint inventions and patents of the CNRS, INRA and François- Rabelais University of Tours in anti-parasitic vaccines, a field in which needs remain very largely unmet. Backed by CapDecisif Management and GIJ Ile-de-France, VitamFero rests on a solid, perfectly validated, scientific foundation that is based on development of live vaccines, attenuated by targeted and total deletion of virulence genes.
www.vitamfero.com

About Genopole The first French biocluster dedicated to genetic research and biotechnologies applied to health and the environment, Genopole gathers together 21 research laboratories, 71 biotechnology firms, 21 technology platforms and university education (Evry-Val-d'Essonne University). Its goal: encourage research development in genomics, post-genomics and associated sciences, and technology transfer to industry; develop high level education in those fields; create and support biotechnology firms. . Genopole is largely financed by public agencies Conseil Régional d'Ile-de-France (30%), Conseil Général de l'Essonne (26,5%) and the French State (15,7%).
www.genopole.fr

About Imaxio
Imaxio SA is a biopharmaceutical company specialized in the area of vaccines.
Using IMX313, its antigen re-engineering technology, Imaxio is developing, both individually and with its partners, recombinant vaccines with improved effectiveness for applications in both human and animal health.
In France, Imaxio already markets Spirolept®, a human vaccine indicated for preventing a work-related infectious disease, and Trolovol®, an orphan drug indicated for a congenital metabolic disease.
Imaxio was developed from Avidis, a spin-off from the Medical Research Council and Cambridge University (UK) created in 2000. The company owns well-founded intellectual property and collaborates with numerous academic partners, including the Jenner Institute at Oxford University.
Imaxio SA is based in Lyon (France). It has 21 employees, nine of whom are engaged in R&D. In 2012 it delivered a turnover of EUR 2.7 million.
www.imaxio.com